Altace and Retinopathy - a phase IV clinical study of FDA data

Summary:

Retinopathy is reported as a side effect among people who take Altace (ramipril), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Humalog, and have Bipolar disorder.

The phase IV clinical study analyzes which people have Retinopathy when taking Altace. It is created by eHealthMe based on reports of 23,086 people who have side effects when taking Altace from the FDA, and is updated regularly.

What is Altace?

Altace has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 23,681 Altace users. Check the latest studies of Altace.

What is Retinopathy?

Retinopathy (acute damage to the retina of the eye) is found to be associated with 440 drugs and 494 conditions by eHealthMe. Check the latest studies of Retinopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

23,086 people reported to have side effects when taking Altace.
Among them, 19 people (0.08%) have Retinopathy.

Among these 19 people:

How long have people been on Altace when they have Retinopathy? *

What is the gender of people who have Retinopathy when taking Altace? *

female: 36.84 %
male: 63.16 %

What is the age of people who have Retinopathy when taking Altace? *

What are other drugs people take besides Altace? *

What are other side effects people have besides Retinopathy? *

Neuropathy Peripheral (surface nerve damage): 7 people, 36.84%
Fatigue (feeling of tiredness): 6 people, 31.58%
Cataract (clouding of the lens inside the eye): 4 people, 21.05%
Stress And Anxiety: 4 people, 21.05%
Vision Blurred: 4 people, 21.05%
Pain: 4 people, 21.05%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 4 people, 21.05%
Diabetes: 4 people, 21.05%
Blindness: 4 people, 21.05%
Rashes (redness): 3 people, 15.79%

What are the existing conditions these people have? *

Hepatitis C: 3 people, 15.79%
Diabetes: 3 people, 15.79%
Bipolar Disorder (mood disorder): 3 people, 15.79%
Pain: 2 people, 10.53%
Ill-Defined Disorder: 2 people, 10.53%
High Blood Cholesterol: 2 people, 10.53%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 2 people, 10.53%
Depression: 2 people, 10.53%
Back Pain: 2 people, 10.53%
Tachyphrenia (abnormally rapid mental activity): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Altace and have Retinopathy?

- Check whether Retinopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Altace:

Altace (23,681 reports)

Retinopathy treatments and more:

Retinopathy (4,577 reports)

Browse all side effects of Altace:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Retinopathy:

Retinopathy (440 drugs)

Browse all the conditions that are associated with Retinopathy:

Retinopathy (494 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ramipril (the active ingredients of Altace) and Altace (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.